Tag: M.W:200-300

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.40000-20-2,5-Bromo-1,10-phenanthroline,as a common compound, the synthetic route is as follows.

To a mixture of 18 (274 mg, 0.63 mmol), 15 (163 mg,0.63 mmol), Pd(PPh3)Cl2 (22 mg, 5 molpercent) and anhyd. K2CO3(261 mg, 1.89 mmol) was added dry DMSO (5 mL) and degassedfor 15 min. The mixture was then heated at 100 C for 24 h. Aftercooling, H2O (10 mL) was added to the reaction mixture and theprecipitate that had formed was collected and washed with H2O(20 mL), EtOH (20 mL), acetone (5 mL) and allowed to dry under vacuum to provide 6 as a tan-colored solid (240 mg, 70percent): mp220 C dec; 1H NMR (500 MHz,CDCl3) d 9.23 (m, 2H), 8.85 (s, 2H),8.75 (d, 2H, J = 4.01 Hz), 8.71 (d, 2H, J = 9.16 Hz), 8.32 (m, 2H),8.10 (d, 2H, J = 8.02 Hz), 7.91 (dt, 2H, J = 8.02, 1.72 Hz), 7.83 (s,1H), 7.69 (m, 3H), 7.63 (m, 1H), 7.38 (m, 2H); 13C NMR(125 MHz, DMSO-d6) d 156.4, 155.4, 150.8, 150.4, 149.9, 149.5,146.4, 145.7, 140.1, 138.1, 137.9, 137.6, 136.9, 134.6, 131.5,128.4, 127.8, 127.6, 127.5, 125.2, 124.3, 123.9, 121.5, 118.5.

40000-20-2, As the paragraph descriping shows that 40000-20-2 is playing an increasingly important role.

Reference£º
Article; Nair, Neelima V.; Zhou, Rongwei; Thummel, Randolph P.; Inorganica Chimica Acta; vol. 454; (2017); p. 27 – 39;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

485-71-2, Cinchonidine is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

Step B1: (9R)-1-[3,5-Bis(trifluoromethyl)benzyl]cinchonan-1-ium-9-ol bromide [table-us-00013-en] d Materials FW Mass Volume mol Equiv. (g/mL) Cinchonidine 294.39 6.1 kg 20.72 1 3,5-Bis(trifluoro-methyl)benzylbromide 307.03 7.0 kg 4.19 L 22.8 1.1 1.671 IPA 66 L (0217) 3,5-Bis(trifluoromethyl)benzyl bromide (7.0 kg) was dissolved in isopropyl alcohol (IPA, 60 L) at 23 C. under nitrogen. To the stirred light yellow solution was added cinchonidine (6.1 kg) in portions over 20 minutes (no exotherm), affording a white slurry. Additional IPA (6 L) was added to rinse all the cinchonidine down into the reaction mixture. The slurry was heated to gentle reflux, reaching an internal temperature of 80-82.5 C. The mixture became less viscous while being heated, and once the temperature had reached 60.6 C. the last of the cinchonidine had dissolved to give a dark yellow solution. Once the mixture had reached gentle reflux, the reaction was seeded by the addition of (9R)-1-[3,5-Bis(trifluoromethyl)benzyl]cinchonan-1-ium-9-ol bromide (62.3 g, 0.104 mol, 0.5 mol % relative to cinchonidine starting material), which led to the immediate precipitation of the product. The mixture was maintained at gentle reflux for 3.5 h, then heating was ceased and the orange slurry was allowed to cool to room temperature (21 C.) with stirring overnight. (0218) After cooling, the mixture was filtered, and the pink product cake was washed with fresh IPA (1¡Á10 L then 1¡Á30 L) to remove unreacted starting materials and most of the color, and dried under vacuum with a nitrogen sweep to afford the title product.

485-71-2, The synthetic route of 485-71-2 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; Merck Sharp & Dohme Corp.; Bell, Ian M.; Fraley, Mark; Gallicchio, Steven N.; Ginnetti, Anthony; Mitchell, Helen J.; Paone, Daniel V.; Staas, Donnette D.; Wang, Cheng; Zartman, C. Blair; Stevenson, Heather E.; (30 pag.)US9499541; (2016); B2;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

99970-84-0,With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.99970-84-0,[2,2′-Bipyridine]-4,4′-dicarbaldehyde,as a common compound, the synthetic route is as follows.

{RuCl(p-cymene)}2(50 mg, 0.08 mmol) and DiPy-G1-MEH (276 mg, 0.16 mmol) were dissolved in distilled DMF (25 mL). The reaction mixture was heated at 80 C. under nitrogen for 4 hours. Then, 2,2′-bipyridine-4,4′-dicarboxaldehyde (Dcbpy) (40 mg, 0.16 mmol) was added and refluxed at 150-160 degrees C. for another 4 hours under reduced light to avoid isomerization (2,2′-bipyridine-4,4′-dicarboxaldehyde was prepared according to the method described in N. Garelli et al, J. Org. Chem. 1992, 57, 3046). Subsequently, an excess of NH4NCS (310 mg, 4.1 mmol) was added to the mixture and heated at 150 C. for a further 4 h. The reaction mixture was cooled to room temperature and the solvent was removed by using a raotary evaporator under vacuum. Water (20 mL) was added to the flask and the insoluble solid was collected on a sintered glass crucible by suction filtration, and washed with distilled water. The crude complex was dissolved on a solution of tetrabutylammonium hydroxide (TBAH) in methanol (5 mL). the concentrated solution was charged onto a Sephadex LH-20 column and eluted with methanol. The main band was collected and concentrated. The required complex was isolated upon addition of 0.01M HNO3.

As the paragraph descriping shows that 99970-84-0 is playing an increasingly important role.

Reference£º
Patent; Isis Innovation Limited; Burn, Paul Leslie; An, Byeong-Kwan; Meredith, Paul; Deceglie, Michael Gardner; US8598350; (2013); B2;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

153-94-6, H-D-Trp-OH is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

To a suspension of (R)-2-Amino-3-(lH-indol-3-yl)-propionic acid 2 (0.23 g, 1.12 mmol) (Alfa-Aesar, A- 18426) in acetone (3 mL) was added 2M sodium carbonate (1 mL) to stir at room temperature for 30 minutes. To this mixture was added bromosulfonyl chloride 1 (0.13g, 0.5 mmol) (Alfa-Aesar, A-14677) at 0 0C to stir for 15 minutes. The reaction mixture was stirred further for 1 hour at room temperature. After pouring into water (20 mL), the solution was washed with ether (x3). The aqueous layer was acidified with IM HCl, followed by extraction with ethyl acetate (x3). The combined organic extracts were then washed with brine and dried (Na2SC^) to provide the crude (R)-2-(5-Bromo- thiophene-2-sulfonylamino)-3-(lH-indol-3-yl)-propionic acid product (3) (O.lg, 74 %). LC-MS (ES+) 429, 431; (ES-) 427, 429.A portion of the crude (R)- 2-(5-Bromo-thiophene-2-sulfonylamino)-3-(lH-indol-3-yl)- propionic acid product (3) was taken to the next step without further purification.

153-94-6, The synthetic route of 153-94-6 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; AQUILUS PHARMACEUTICALS, INC; SUCHOLEIKI, Irving; WO2010/75287; (2010); A2;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.92149-07-0,4,7-Dimethoxy-1,10-phenanthroline,as a common compound, the synthetic route is as follows.

92149-07-0, Under an argon atmosphere, add anhydrous Fe(acac)3 (211.8mg, 0.6mmol) to a 50mL Schlenk flask, and dissolve it in 6mL of anhydrous ethanol at 60 C; Then, a solution of 4,7-dimethoxy-1,10-phenanthroline (144.0 mg, 0.6 mmol) in ethanol (4 mL) was added dropwise to the system. The reaction was carried out at 60 C for half an hour, and then returned to room temperature and stirred overnight. The filtrate was collected by filtration, concentrated, washed twice with cold ethanol, and dried under vacuum for 12 h to obtain a red-brown solid product 8 with a yield of 65%.

As the paragraph descriping shows that 92149-07-0 is playing an increasingly important role.

Reference£º
Patent; Chinese Academy Of Sciences Tsingtao Biological Energies And Process Institute; Wang Qinggang; Wang Liang; Zhu Guangqian; Zhang Xianhui; Jing Chuyang; (29 pag.)CN110452272; (2019); A;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.787-70-2,[1,1′-Biphenyl]-4,4′-dicarboxylic acid,as a common compound, the synthetic route is as follows.,787-70-2

To a stirred solution of biphenyl-4,4′-dicarboxylic acid (500 mg, 2.06 mmol) in 10 mL of DMF was added N-hydroxysuccinimide (594 mg, 5.16 mmol) and dicyclohexylcarbodiimide (1.06 g, 5.16 mmol) at 0C and the mixture stirred at RT overnight. The reaction mixture was filtered and the filtered cake was washed with EtOAc. The washings and filtrate were combined, washed with brine solution (3×20 mL), dried over anhydrous sodium sulfate and concentrated under reduced pressure to afford a crude product that was dissolved in DCM and again filtered. The DCM layer was concentrated under reduced pressure to afford desired product (600 mg).

As the paragraph descriping shows that 787-70-2 is playing an increasingly important role.

Reference£º
Patent; MEDIVATION TECHNOLOGIES, INC.; RAI, Roopa; PHAM, Son Minh; HART, Barry Patrick; (374 pag.)WO2017/19830; (2017); A1;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

787-70-2, [1,1′-Biphenyl]-4,4′-dicarboxylic acid is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

787-70-2, General procedure: A mixture of 1,3-BPEB(14.2 mg, 0.05 mmol), 1,4-BDC (8.3 mg, 0.05 mmol),Cd(NO3)24H2O (15.5 mg, 0.05 mmol), and DMF (1.5 mL) – water(0.5 mL) mixture were placed in a 10 mL glass bottle. This bottlewas sealed and kept at 100 C for 48 h, followed by cooling to roomtemperature over 24 h. Orange block crystals 1 were obtained in a61.4% yield (17.6 mg, based on cadmium). Anal. calc. forC84H64N6O14 Cd3: C 58.70, H 3.75, N 4.89. Found: C 58.64, H 3.70, N4.81.

787-70-2 [1,1′-Biphenyl]-4,4′-dicarboxylic acid 13084, acatalyst-ligand compound, is more and more widely used in various fields.

Reference£º
Article; Liang, Rui; Yue, Fangfang; Wang, Yuting; Guo, Yongkang; Xuan, Xiaopeng; Journal of Molecular Structure; vol. 1119; (2016); p. 301 – 307;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.2304-30-5,Tetrabutylphosphonium chloride,as a common compound, the synthetic route is as follows.

EXAMPLE 1 Preparation of 2,4,6-tris(o-aminophenylthiomethyl)mesitylene A 2-liter glass reaction vessel equipped with a Teflon stirrer, reflux condenser, addition funnel, 2-thermometers and an electrical heater was charged with 243 g water and 104.2 g sodium hydroxide pellets. After boiling under a nitrogen atmosphere for 5 minutes, 167.8 g benzothiazole was gradually added to the contents of the reactor over 50 minutes. The resultant mixture was then heated at the boiling point for 2 hours. A solution of 0.5 g tetrabutyl phosphonium chloride (50% in toluene) and 50 g toluene was then added, which cooled the reaction mixture to 90 C. A solution of 100 g 2,4,6-tris(chloromethyl)mesitylene in 300 g of warm toluene was added over a 15 minute period and the resultant mixture was heated at the boiling point for 2 hours. The aqueous phase of the reaction mixture was then removed and the organic phase washed with 100 g hot water. The residual water was removed by azeotropic distillation. After being filtered the toluene solution gradually cooled to room temperature, during which time a slightly off-white solid crystallized. The solid was filtered off, washed sequentially with cold toluene and heptane and then dried under reduced pressure at 90 C. The product weighed 164.7 g melted from 161 to 166 C. and exhibited an amine equivalent of 181. The theoretical amine equivalent for the expected product, 1,3,5-tris(o-aminophenylthiomethyl)mesitylene is 178.

2304-30-5, As the paragraph descriping shows that 2304-30-5 is playing an increasingly important role.

Reference£º
Patent; M&T Chemicals Inc.; US4187250; (1980); A;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

128143-89-5, 4′-Chloro-2,2′:6′,2”-terpyridine is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

4′-(2-Aminoethanesulfanyl)-2,2′:6′,2”-terpyridine (2a) was prepared from reaction of the 4′-chloroterpyridine 8a (at 50 C for 3 h) or the 4′-iodoterpyridine 7a (at 70 C for 2 h) with 2-aminoethanethiol hydrochloride and sodium hydride in DMF. The reactions gave the target compound 2a in 75% and 86% yields, respectively.The 1H and 13C NMR spectral data of 2a were consistentwith literature data., 128143-89-5

The synthetic route of 128143-89-5 has been constantly updated, and we look forward to future research findings.

Reference£º
Article; Lin, Chih-Pei; Florio, Pas; Campi, Eva M.; Zhang, Chunfang; Fredericks, Dale P.; Saito, Kei; Jackson, W. Roy; Hearn, Milton T.W.; Tetrahedron; vol. 70; 45; (2014); p. 8520 – 8531;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.168646-54-6,5,6-Diamino-1,10-phenanthroline,as a common compound, the synthetic route is as follows.

[Cu(CH3CN)4]ClO4 (32.6 mg, 0.100 mmol) was added to a DCMsolution (about 12 mL) of dap (10.7 mg, 98percent, 0.0500 mmol) andxantphos (59.0 mg, 98percent, 0.100 mmol) under a stream of dry argonby using Schlenk techniques at room temperature and a vacuumlinesystem, then orange-red solution was obtained quickly andstirred for 1 h at room temperature. The above process can alsobe carried out in air with the existence of oxygen. After filtrationthrough absorbent cotton, layering n-hexane onto the DCM solutionin air produced the product as bluish violet to black-blue blockcrystals in 76percent yield (63.0 mg). Anal. Calc. for C90H72Cl2Cu2N4O10P4(1b): C, 63.97; H, 4.30; N, 3.32. Found: C, 64.25; H, 4.35; N, 3.26percent.ESI-MS (m/z): 1589.25 {[Cu2(l-pdi)(xantphos)2]ClO4}+ (calcd1589.27); 849.1963 [Cu(pdi)(xantphos)]+ (calcd 849.1968);745.153 [Cu2(l-pdi)(xantphos)2]2+ (calcd 745.159); 641.1222[Cu(xantphos)]+ (calcd 641.1224). 1H NMR (400 MHz, DMSO-d6,delta, ppm): 13.190 (s, 2H, CNH), 9.030 (d, 2H, J = 8.0 Hz), 8.452 (d,2H, J = 4.8 Hz), 7.888 (dd, 2H, J = 8.0 Hz, J0 = 1.2 and 0.8 Hz),7.846?7.814 (m, 4H), 7.340?7.149 (m, 36H), 6.983?6.938 (m, 8H),6.729?6.694 (m, 2H), 6.650?6.615 (m, 2H), 1.732 (s, 6H, CH3),1.653 (s, 6H, CH3). 31P{1H} NMR (400 MHz, DMSO-d6, delta, ppm):5.980, 12.816. Characteristic IR spectrum (KBr, cm-1): 3258m(NH), 2961m (CH3), 2923w (CH3), 2858w (CH3); 1097s (ClO4).

168646-54-6, The synthetic route of 168646-54-6 has been constantly updated, and we look forward to future research findings.

Reference£º
Article; Yao, Xi-Xi; Guo, Ya-Meng; Liu, Rong; Feng, Xiao-Yan; Li, Hao-Huai; Liu, Nian; Yang, Feng-Lei; Li, Xiu-Ling; Polyhedron; vol. 92; (2015); p. 84 – 92;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI